Join Now

It's Free - Always

First Name
Last Name
Zip/Postal Code
Country of Practice
Confirm Password
I have read and agree to the Participant Terms and Conditions

is already registered on QuantiaMD

Is this you? Enter your password to continue.
The password you entered is incorrect. Please try again or choose a different option.
Forgot your password? Click here and password reset instructions will be sent to the above email address.
Need more help? Contact Member Support

is already registered on QuantiaMD

Instructions to reset your password have been sent to the following email address:

For further assistance, please Contact Member Support
Thank you for registering on QuantiaMD.

Forgot your password?

Please enter your email address below, and we will send you a link to reset your password.

Earn this Certificate
0 out of 3 completed
Hepatitis C: A 360° View of Treatment

Leaders in the management of hepatitis C share their expert advice on how to treat this highly common bloodborne infection. They offer perspectives from several different roles to provide you with a 360° view of a hepatitis C patient’s treatment plan. Hear their insights into the future role that various healthcare providers will play in the treatment and management of this disease.

Edwin DeJesus, MD
Medical Director, Orlando Immunology Center
Start the next presentation
You've completed 0 out of 3 presentations
Expert Practice Series Presentations
Edwin DeJesus, MD
Medical Director, Orlando Immunology Center
Trevor Hawkins, MD
Associate Clinical Professor, Department of Family Practice, University of New Mexico, Medical Director and Principal Physician, Southwest C.A.R.E. Center, Santa Fe, NM
Donald P. Kotler, MD
Chief, Division of Gastroenterology, Mount Sinai St. Luke's Roosevelt
Latest Comments
"Great presentation! Any information on the newer agents use and efficacy (harvoni, etc?) I assumed the care of a patient who was treated with Harvoni who now has  collagen-vascular antibodies positive & is seeing a rheumatologist. How common is this?"
laura anders, MD
"I think until we get to a pangenotypic agent that has few drug interactions, that is not altered by diminished renal function, and is not associated with the need to evaluate for viral variants that few primary care physicians will choose to undertake prescribing therapy. Additionally, PCPs seem uncomfortable assessing the degree of liver fibrosis."
Richard Mayhew, MD
Terms | Privacy | FAQ | | 1-800-773-4162
©2016 Quantia, a wholly owned subsidiary of Aptus Health, Inc.